Dr. Somnath Mukhopadhay is a highly accomplished Interventional Cardiologist known for managing complex cardiac conditions with precision and care. He has performed more than 4,000 cardiac interventions and is widely respected for his clinical judgment and patient-focused approach. His expertise, combined with strong academic credentials and research involvement, makes him one of the leading heart specialists in Kolkata.
Educational Qualification:
- MBBS – NRS Medical College & Hospital, WBUHS (2003-2009)
- MD (General Medicine) – Medical College Kolkata, WBUHS (2012-2015)
- DM (Cardiology) – Medical College Kolkata, WBUHS (2015-2018)
Professional Experience:
- Consultant Interventional Cardiologist at Manipal Hospitals, Broadway
- Extensive experience across leading hospitals in Kolkata
- Performed 2000+ coronary angiograms and 700+ angioplasties
- Over 500 pacemaker implantations and multiple ICD/CRT procedures
- Performed over 200 complex coronary angioplasties, managing advanced and high-risk coronary artery diseases with precision.
- Experienced in structural heart interventions, including PDA, ASD, and VSD device closures.
- Routinely performs 300+ echocardiograms per month, including advanced transesophageal echocardiography (TEE).
- Skilled in advanced intracoronary imaging and physiology tools such as IVUS, FFR, and OCT, ensuring accurate diagnosis and optimal interventional outcomes.
- Registered with the West Bengal Medical Council
- Registration Number: 64713
Awards & Achievements:
- First Rank in DM Cardiology – Medical College Kolkata (2018)
- Sub-Investigator, ODYSSEY (EAST) Study – PCSK9 inhibitors
- Honours in Biochemistry during MBBS
- Class Assistant in ENT during undergraduate training
Professional Membership & Fellowship:
- FAPSIC – Fellow of the Asian Pacific Society of Interventional Cardiology (2023)
- FESC – Fellow of the European Society of Cardiology (2024)
Publications:
- Published research in Egypt Heart Journal (2021) titled
“Cardiovascular disease risk factors among undergraduate medical students in a tertiary care centre of eastern India: a pilot study” - Sub-Investigator, ODYSSEY (EAST) Study sponsored by Sanofi Synthelabo (India), focused on PCSK9 inhibitors in cardiovascular disease management.
.png)
.png)